Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced positive results from its Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader medicine. The study demonstrated over 90% mean STAT6 degradation in blood at all doses above 1.5 mg and complete STAT6 degradation in both blood and skin at all multiple ascending doses equal to or greater than 50 mg. KT-621 showed a safety profile similar to placebo, with no serious adverse events reported. The trial's results indicate potential for treating IL-4/IL-13-driven allergic diseases. Kymera plans to begin two parallel Phase 2b trials in atopic dermatitis and asthma in late 2025 and early 2026, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.